A case of vascularized corneal opacity treated with aflibercept
Background: Corneal neovascularization (CNV) is a serious condition that can lead to a profound decline in vision. Current research on treating CNV with angiogenesis inhibitors is underway in numerous centers, and a number of studies have demonstrated the efficacy of this approach. Purpose: To pr...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ukrainian Society of Ophthalmologists
2020-02-01
|
| Series: | Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://www.ozhurnal.com/en/archive/2020/1/10-fulltext |
| _version_ | 1827580965950586880 |
|---|---|
| author | A.S. Cholak I.O. Nasinnyk P.O. Kostenko S.A. Iakimenko A.R. Korol |
| author_facet | A.S. Cholak I.O. Nasinnyk P.O. Kostenko S.A. Iakimenko A.R. Korol |
| author_sort | A.S. Cholak |
| collection | DOAJ |
| description | Background: Corneal neovascularization (CNV) is a serious condition that can lead to a profound decline in vision. Current research on treating CNV with angiogenesis inhibitors is underway in numerous centers, and a number of studies have demonstrated the efficacy of this approach.
Purpose: To present a case of corneal neovascularization treated with aflibercept.
Material and Methods: An ocular examination included visual acuity assessment, biomicroscopy, anterior eye photography and fluorescein angiography (FA). In addition, an area of CNV was assessed before and 6 months after a single subconjunctival injection of 4 mg (0.1ml) aflibercept.
Results: An area of CNV decreased from 38,081 pixels before injection to 20,782 at 6 months, with a reduction in 17,299 pixels.
Conclusion: In the case reported here, a single subconjunctival injection of 4 mg (0.1ml) aflibercept was found to be effective for reducing corneal neovascularization at 6 weeks. |
| first_indexed | 2024-03-08T22:28:40Z |
| format | Article |
| id | doaj.art-be4d686d64e541c6878bd24dc3cf6ba4 |
| institution | Directory Open Access Journal |
| issn | 2412-8740 |
| language | English |
| last_indexed | 2024-03-08T22:28:40Z |
| publishDate | 2020-02-01 |
| publisher | Ukrainian Society of Ophthalmologists |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj.art-be4d686d64e541c6878bd24dc3cf6ba42023-12-18T09:13:13ZengUkrainian Society of OphthalmologistsJournal of Ophthalmology2412-87402020-02-011545610.31288/oftalmolzh202015456A case of vascularized corneal opacity treated with aflibercept A.S. Cholak0I.O. Nasinnyk1P.O. Kostenko2S.A. Iakimenko3A.R. Korol4Filatov Institute of Eye Diseases and Tissue Therapy, National Academy of Medical ScienceFilatov Institute of Eye Diseases and Tissue Therapy, National Academy of Medical ScienceFilatov Institute of Eye Diseases and Tissue Therapy, National Academy of Medical ScienceFilatov Institute of Eye Diseases and Tissue Therapy, National Academy of Medical ScienceFilatov Institute of Eye Diseases and Tissue Therapy, National Academy of Medical ScienceBackground: Corneal neovascularization (CNV) is a serious condition that can lead to a profound decline in vision. Current research on treating CNV with angiogenesis inhibitors is underway in numerous centers, and a number of studies have demonstrated the efficacy of this approach. Purpose: To present a case of corneal neovascularization treated with aflibercept. Material and Methods: An ocular examination included visual acuity assessment, biomicroscopy, anterior eye photography and fluorescein angiography (FA). In addition, an area of CNV was assessed before and 6 months after a single subconjunctival injection of 4 mg (0.1ml) aflibercept. Results: An area of CNV decreased from 38,081 pixels before injection to 20,782 at 6 months, with a reduction in 17,299 pixels. Conclusion: In the case reported here, a single subconjunctival injection of 4 mg (0.1ml) aflibercept was found to be effective for reducing corneal neovascularization at 6 weeks.https://www.ozhurnal.com/en/archive/2020/1/10-fulltextcorneal neovascularizationfluorescein angiographyangiogenesis inhibitoraflibercept |
| spellingShingle | A.S. Cholak I.O. Nasinnyk P.O. Kostenko S.A. Iakimenko A.R. Korol A case of vascularized corneal opacity treated with aflibercept Journal of Ophthalmology corneal neovascularization fluorescein angiography angiogenesis inhibitor aflibercept |
| title | A case of vascularized corneal opacity treated with aflibercept |
| title_full | A case of vascularized corneal opacity treated with aflibercept |
| title_fullStr | A case of vascularized corneal opacity treated with aflibercept |
| title_full_unstemmed | A case of vascularized corneal opacity treated with aflibercept |
| title_short | A case of vascularized corneal opacity treated with aflibercept |
| title_sort | case of vascularized corneal opacity treated with aflibercept |
| topic | corneal neovascularization fluorescein angiography angiogenesis inhibitor aflibercept |
| url | https://www.ozhurnal.com/en/archive/2020/1/10-fulltext |
| work_keys_str_mv | AT ascholak acaseofvascularizedcornealopacitytreatedwithaflibercept AT ionasinnyk acaseofvascularizedcornealopacitytreatedwithaflibercept AT pokostenko acaseofvascularizedcornealopacitytreatedwithaflibercept AT saiakimenko acaseofvascularizedcornealopacitytreatedwithaflibercept AT arkorol acaseofvascularizedcornealopacitytreatedwithaflibercept AT ascholak caseofvascularizedcornealopacitytreatedwithaflibercept AT ionasinnyk caseofvascularizedcornealopacitytreatedwithaflibercept AT pokostenko caseofvascularizedcornealopacitytreatedwithaflibercept AT saiakimenko caseofvascularizedcornealopacitytreatedwithaflibercept AT arkorol caseofvascularizedcornealopacitytreatedwithaflibercept |